B. Riley Securities Downgrades Silk Road Medical to Neutral, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Neil Chatterji has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Neutral and lowered the price target from $54 to $14.
October 11, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Silk Road Medical's stock rating has been downgraded from Buy to Neutral by B. Riley Securities, with a significant reduction in price target from $54 to $14.
The downgrade from Buy to Neutral indicates a less optimistic outlook for the company's stock. The significant reduction in price target from $54 to $14 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100